NCT07017478 Mood Effects of Serotonin Agonists: Depression
| NCT ID | NCT07017478 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Chicago |
| Condition | LSD |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2025-06-09 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 48 participants in total. It began in 2025-06-09 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
Eligibility Criteria
Inclusion Criteria: * English Fluency * high school education or higher * BMI between 19-30 kg/m2 Exclusion Criteria: * individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease) * high blood pressure (\>140/90) * current suicidal ideation or suicide attempt in past 12 months * past year severe substance use disorder * personal or first-degree relative with history of psychosis * currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks) * active panic disorder * severe obsessive-compulsive disorder * severe post-traumatic stress disorder * women who are pregnant or planning to become pregnant
Contact & Investigator
Hanna Molla
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT07017478 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying LSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07017478 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07017478 currently recruiting?
Yes, NCT07017478 is actively recruiting participants. Contact the research team at hmolla@uchicago.edu for enrollment information.
Where is the NCT07017478 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07017478 clinical trial?
NCT07017478 is sponsored by University of Chicago. The principal investigator is Hanna Molla at University of Chicago. The trial plans to enroll 48 participants.